Survey Outcome on Immunogenicity Risk Assessment Tools for Biotherapeutics: an Insight into Consensus on Methods, Application, and Utility in Drug Development
Jochem Gokemeijer(Bristol-Myers Squibb (Germany)), Sofie Pattijn, Shibani Mitra‐Kaushik(Takeda (United States)), Laurent Malherbe(Versiti Blood Center of Wisconsin), Vibha Jawa(Bristol-Myers Squibb (Germany)), Shan Chung, Sophie Tourdot(Pfizer (United States)), Kasper Lamberth(Novo Nordisk (Denmark)), Theresa J. Goletz(GlaxoSmithKline (United States)), Qui Phung, Jennie R. Lill, Karen Liao(United States Military Academy), Alan Goggins(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yi Wen(Eli Lilly (United States)), Inderpal Singh(Spark Therapeutics (United States)), Seema Kumar(Merck & Co., Inc., Rahway, NJ, USA (United States)), Bonita Rup, Brian Roberts(Providence College), Robin E. Walsh(Eli Lilly (United States)), Swati Gupta(AbbVie (United States)), Michael D. Swanson(Janssen (United States)), Mark A. Kroenke(Amgen (United States))
Cited by 22
Related Papers
Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
|Molecular Therapy — Methods & Clinical Development|2022|113